title: [Allogeneic hematopoietic stem cell transplantation in elderly].
abstract: Most of patients with hematological malignancies are elderly (more than 60  years). Allogeneic stem cell transplantation is an important and effective treatment for most of these diseases. However, the toxicity and the supposed frailty of elderly patients, have limited the applicability of allogeneic transplantation for these patients. Elderly patients are at high risk to develop life-threatening complications, if allogeneic transplantation is performed with myeloablative conditioning regimens and using bone marrow stem source. Since more than 10 years, reduced intensity conditioning regimen have been developed, allowing to overcome the age as contra-indication for allogeneic transplantation. On the other hand, it is the presence of comorbidities which identify frail patients. For these subjects, allogeneic transplantation should be not indicated. Furthermore, advances in the supportive care and the development of new molecules could allow to reduce the toxicity of myeloablative conditioning regimens and thus to offer more intensive regimens before transplantation also in elderly population.
authors.affiliation: Institut Paoli-Calmettes, Marseille, France. luca.castagna@humanitas.it
authors.forename: Luca
authors.initials: L
authors.lastname: Castagna
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Sabine
authors.initials: S
authors.lastname: Furst
mesh_terms: D000367:Age Factors; D000368:Aged; D015897:Comorbidity; D000075202:Contraindications; D016330:Frail Elderly; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous